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Background: During the last few years it has been shown in several laboratories that Celecoxib (Cx), a non-steroidal
anti-inflammatory agent (NSAID) normally used for pain and arthritis, mediates antitumor and antiangiogenic effects.
However, the effects of this drug on a tumor cell line resistant to chemotherapeutical drugs used in cancer have not
been described.
Herein we evaluate the angiogenic and antitumor effects of Cx in the development of a drug-resistant mammary
adenocarcinoma tumor (TA3-MTXR).
Results: Cx reduces angiogenesis in the chick embryonic chorioallantoic membrane assay (CAM), inhibits the growth
and microvascular density of the murine TA3-MTXR tumor, reduces microvascular density of tumor metastases, promotes
apoptosis and reduces vascular endothelial growth factor (VEGF) production and cell proliferation in the tumor.
Conclusion: The antiangiogenic and antitumor Cx effects correlate with its activity on other tumor cell lines,
suggesting that Prostaglandins (PGs) and VEGF production are involved. These results open the possibility of using
Celecoxib combined with other experimental therapies, ideally aiming to get synergic effects.
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Non-steroidal anti-inflammatory drugs (NSAIDs) is a
heterogeneous group of drugs associated with inhibition
of the inflammation process, mainly targeting enzymes
such as cyclooxygenase (COX), involved in the synthesis
of prostaglandins (PG) from arachidonic acid. However,
NSAIDs have been related to COX-2 and COX-1 inhi-
bition, considering that COX-1 inhibition may cause
gastrointestinal bleeding and ulcers, and COX-2 inhi-
bition is associated to anti-inflammatory, antipyretic and
analgesic effects.
COX-2 has not been only related to inflammation but
also angiogenesis, proliferation and tumor growth. There
is evidence of an overexpression of COX-2 in a variety
of cancers [1-3]. Patients over-expressing COX-2 in pan-
creatic tumor cells have a worse prognosis than those
who do not [4,5].* Correspondence: dlemus@med.uchile.cl
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unless otherwise stated.Celecoxib (Cx) is a selective COX-2 inhibitor approved
by the Food and Drug Administration (FDA) for
rheumatoid arthritis, osteoarthritis and acute pain, but
in the last years it has been proposed as an agent that
can intervene signal transduction pathways associated
with COX-2 expression and increase the levels of
endogenous inhibitors of angiogenesis, called endostatins
[6,7]. Moreover, NSAIDs decrease tumor progression for
some malignancies such as colon cancer [8-10]. For this
reason, Cx has been proposed for the treatment of colon,
pancreatic, and breast cancer, suppressing angiogenesis
and promoting apoptosis [5,10,11]. Finally Cx inhibits
the growth of a meningioma in vivo, decreases COX-2
activity and lowers PG concentrations and angiogenesis,
promoting higher rates of apoptosis [4].
Considering these results altogether, Cx has been related
to antitumoral and antiangiogenic effects. Konturek et al.
[12] proposed that PG-E bind to EP receptor mediates
apoptosis evasion, angiogenesis, proliferation and migra-
tion. Moreover, PG-E modulates survivin and VEGF
levels, which are associated to evasion of apoptosis andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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inhibition mediated by Cx could reduce tumor growth,
angiogenesis and promote apoptosis, through a reduced
PG production. This effect is relevant in acquired resis-
tance to conventional therapy such as chemotherapy,
because Cx effect is independent of the chemotherapy
action mechanism. For this reason, we hypothesize that
Cx reduces angiogenesis and tumor growth in a mammary
tumor cell line resistant to chemotherapy such as TA3-
MTXR. Previously, we have shown that Cx at 1000 ppm
reduces liver metastasis but not lung metastasis, in mice
with a multiresistant adenocarcinoma TA3 [13]. On the
other hand, Sulindac, a NSAID that inhibits COX-1 and
COX-2 activity, reduces angiogenesis in an in vivo model
[14]. Herein we evaluate the angiogenic and antitumor
effects of Cx in the development of a drug-resistant mam-
mary adenocarcinoma tumor.Figure 1 Cx reduces microvascular density in the chick-CAM
assay. PBS (Control), Cx at 500, 1000 and 2000 ppm was instilled on
chick chorioallantoic membranes (CAM) as described in Methods.
Membranes were fixed and stained with H&E-Alcian Blue. Membranes
were visualized (A) and number of vessels per 9000 μm2 was counted
(B). Blood vessels are represented by arrows. (**: p < 0.001; ***: p <
0.0001). Scale bar: 100 μm.Results
Cx reduces microvascular density in the chick-CAM assay
The potential antiangiogenic effect of Cx in CAM assay
was assessed when 500–2000 ppm of Cx were assayed.
PBS was used as negative control. The chick CAM is a
vascular membrane formed by two mesodermal layers,
allantois and chorionic epithelium. Transversal sections of
CAM showed a chorionic epithelium with small blood
vessels, a mesenchyme with medium-size blood vessels
and allantoic epithelium. Morphologically, tissue sections
treated with Cx at 500 and 1000 ppm showed a normal
morphology without apparent damage. However, Cx used
at 2000 ppm, induced tissue alterations, mainly epithelial
destruction (Figure 1A).
Microvascular density analysis showed that number of
vessels/9000 μm2 on CAM was 15.76 ± 0.38 for PBS, 11.50 ±
0.40 for Cx 500 ppm, 11.36 ± 0.22 for Cx 1000 ppm and
8.27 ± 0.28 for Cx 2000 ppm.
A strong antiangiogenic effect was observed with Cx
used at 500 (p < 0.001), 1000 (p < 0.0001) and 2000 ppm
(p < 0.0001) when is compared with PBS group (Figure 1B).Cx inhibits the growth of a murine A/J mammary tumor
(TA3-MTXR)
Cx effect on the in vivo growth of the TA3-MTXR tumor
cell line was assessed. All tumor-injected mice had similar
thigh size on day 0. This remained constant until day 6,
where an increase in tumor volume could be observed
and measured. From this moment on, treated group (n = 6)
began receiving oral treatment with Cx at 1000 ppm,
with inhibitory effects (p < 0.05) on tumor growth when
compared with control group (n = 6) (Figure 2).
At the 15th day, the control group showed a volume
of 5069 ± 427.1 mm3 and the treated group had a volume
of 3978 ± 385.2 mm3. The treated group presented astatistical significant difference when it was compared
with control group (p = 0.0435).
At the 18th day, a statistically significant difference was
detected when the treated group (4519 ± 376.6 mm3) was
compared with the control group (5727 ± 455.8 mm3)
(p = 0.0341).
At the 19th day, the control group presented a volume
of 6168 ± 550 mm3 while the treated group had a
volume of 4790 ± 463 mm3. These results confirm that
Cx promoted a 22.3% reduction in tumor volume (p =
0.0422). For bioethical rules, assay was stopped at 19th
day, because, one mouse of control group died.
Cx inhibits microvascular density of a murine A/J
mammary tumor (TA3-MTXR)
Histological sections of tumor and lungs were stained
with Arteta for improving blood vessels visualization.
Figure 2 Cx inhibits the growth of a murine A/J mammary
tumor. 900000 tumor cells were inoculated s.c. in the flank of A/J
female mice. Cx treatment and measurement of tumor development
are described in the Methods section. The graph represents the
tumor volume of control (n = 6) and Cx-treated (n = 6) mice. Cx
showed an anti-tumor effect compared with control (p < 0.05). For
bioethical reasons, the experiment was stopped at 19th day. Bars
represent standard errors. Wilcoxon signed rank test p < 0.05.
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zone. The Peripheral zone is an area with fibroblasts,
collagenous fibers and blood vessels. The Central zone
showed necrotic areas, tumor cell pleomorphism and
disorganized small blood vessels, typical architecture of
tumor angiogenesis. The group inoculated only with the
TA3-MTXR tumor (Figure 3A) averaged 43.8 ± 1.74
vessels/field. On the other hand, the group treated with
Cx at 1000 ppm presented 24.1 ± 0.86 vessels/field
(Figure 3B). A significant decrease in the number of
vessels per area was detected in the treated group
(p < 0.0001) (Figure 3C).
Lung sections showed normal parenchyma surroun-
ding a group of tumor cells in a “cannon ball” shape. This
formation had tumor cells, neoangiogenic vessels and a
loss of lung architecture. In lung sections, the control
group (Figure 3D) averaged 284.8 ± 7.21 vessels/field,
while Cx (1000 ppm) the treated animals (Figure 3E)
averaged 258.7 ± 5.65 vessels/field, (p = 0.0031) (Figure 3F).
Cx decreases proliferation of a murine A/J mammary
tumor (TA3-MTXR)
Histological sections of tumor were incubated with a
Rabbit Polyclonal Anti – Human Ki-67 antibody, a pro-
tein associated to cell proliferation. In the control group,
immunomarked cells (Ki-67 positive) were tumor cells,
even when they are surrounded by lymphocytes and
polymorphonuclear cells (Figure 4A). Quantification of
immunomarked cells in tumor showed that the control
group had a Ki-67 relative expression of 1.00 ± 0.14
while the Cx-treated group showed a lower Ki-67
relative expression (0.322 ± 0.060). Low quantities ofimmunomarked cells were found in this group, but all of
this were tumor cells (Figure 4B). Treated group
presented a statistically significant difference when it was
compared with control group (p < 0.0001) (Figure 4C).Cx decreases VEGF production of a murine A/J mammary
tumor (TA3-MTXR)
Histological sections of tumor were incubated with a
Anti-VEGF165 Polyclonal Antibody, which detected the
main protein associated to angiogenesis.
The control group showed a moderate to abundant
presence of VEGF with a cytoplasmic staining pattern of
tumor cells. Quantification of VEGF expression was
1.00 ± 0.100 (Figure 4D). In contrast, the Cx-treated group
showed only a mild to moderate VEGF presence in tumor
with a relative expression of 0.70 ± 0.08 (Figure 4E). The
Cx-treated group showed a statistically significant
difference when it was compared with control group (p =
0.0178) (Figure 4F).Cx promotes apoptosis of a murine A/J mammary tumor
(TA3-MTXR)
Histological sections of lung metastasis were assessed
with a TUNEL Assay for fragmented DNA detection, a
characteristic condition of apoptosis. We observed 7.30 ±
0.39 and 44.6 ± 1.24 apoptotic nuclei/field in lungs from
the control (Figure 4G) and Cx-treated (Figure 4H)
groups, respectively (p < 0.0001) (Figure 4I). We also
observed that, in a primary tumor, apoptosis increased
(p < 0.05) (not shown) after treatment with Cx at 1000 ppm.Discussion
We propose that Cx decreases growth in a drug resistant
mammary adenocarcinoma tumor. Moreover, Cx decreases
angiogenesis and promotes apoptosis in the same tumor
cell line.
Cx inhibits microvascular density in the CAM assay at
different concentrations. This result was useful to define
the optimal concentration in a tumor (Figure 1). Previous
reports demonstrated that COX-2 inhibitors suppressed
angiogenesis on CAM [15]. However, the COX-2 inhibitor
assessed was nimesulide at 100 μmol/L. In our study we
demonstrated that Celecoxib suppressed angiogenesis at
500 ppm and 1000 ppm. Higher doses than 2000 ppm
induces tissue destruction.
Cx inhibits tumor growth in a murine A/J mammary
adenocarcinoma tumor (Figure 2). When Cx has been
used in a particular tumor cell line, results are rather
contradictory among different authors.
Raut et al. [16] achieved a reduction in the L3.6pl
pancreatic tumor line impact at only very low concentra-
tions (10 mg/kg) of Cx injections.
Figure 3 Cx inhibits microvascular density of a murine A/J mammary tumor (TA3-MTXR). Histological sections stained with Arteta were
visualized at 400× in an optical microscopy and blood vessels were counted. Left panel shows a representative section of untreated primary
tumor (A) or Cx-treated (B). Blood vessels were counted (C) and a statistical significance was found (***: p < 0.0001). Right panel shows a representative
section of untreated lung metastasis (D) or Cx-treated (E). Blood vessels were counted (F) and a statistical significance was found (*: p = 0.0031).
Blood vessels are represented by black arrows.
Rosas et al. Biological Research 2014, 47:27 Page 4 of 9
http://www.biolres.com/content/47/1/27Ragel et al. [4] showed that Cx at 1500 ppm orally
administered reduced the growth of the tumor line
IOMM-Lee.
Klenke et al. [17] used injections of Cx in a 30 mg/kg
concentration, obtaining a decrease of an A549 lung
tumor, between days 21 and 28.
Xu et al. [5] used Panc-1 tumor cell line and observed
a decrease in tumor volume and weight when oral Cx
was used at 1500 ppm.
Harris et al. [18] and Jang et al. [19] generated a tumor
using orally administration of DMBA and 1500 ppm
of Cx for treatment. Only the first group obtained a
significant decrease in tumor volume. Dai et al. [20]
demonstrated that Celecoxib 1000 mg/kg inhibited rat
carcinogenesis and cancer development.Although results and doses may vary for each tumor
cell line, our study demonstrated that oral administra-
tion of Cx at 1000 ppm reduced tumor growth in the
TA3-MTXR line. Moreover, since 15th to 19th day there
was a significant difference between both groups. It is
important to consider the number of animals. In our
study, twelve mice divided in two groups were used. Al-
though the number of animals was low, the results were
significant. Our results propose that Cx reduces angio-
genesis and proliferation and promotes apoptosis, as
reflected in a reduction of tumor growth. However, this
effect does not seem to prevent metastasis from primary
tumor. Previously, we have shown that lung metastasis
do not decrease in the Cx-treated group [13]. Accor-
dingly with this result, Cx could not reduce proliferation
Figure 4 Cx decreases proliferation, VEGF production and promotes apoptosis of a murine A/J mammary tumor (TA3 MTXR). Tumor
samples showed a decreased proliferation in Cx-treated group (B), when compared with control group (A). Relative expression is represented
(C) (***: p < 0.0001) VEGF expression was reduced in treated group (E) when it was compared with control group (D). Relative expression is
represented (F) (*: p = 0.0178). Apoptotic nuclei of lung sections were labeled with a TUNEL assay and treated group (H) showed an increased
apoptotic nuclei/field when it was compared with control group (G). Apoptotic nuclei per field are represented (I) (***: p < 0.0001).
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nary metastases, but we do not make a comparison
between flank tumor and metastasis. This proposal
needs to be clarified in further investigations.
Our results show that Cx inhibits microvascular den-
sity of a murine A/J mammary tumor and lung metasta-
sis. The microvascular density comparison succeeded in
establishing that there were significant differences in the
tumor and lung when treated with Cx, reducing vascular
density (Figure 3C, F). Other organs like the spleen and
heart did not differ because they were not invaded by
tumor cells (data not shown). The process of tumor
angiogenesis is associated with the formation of new
blood vessels, which are tortuous, small and abundant in
areas of hypoxia. Since angiogenic microvessels gene-
rated by pro-angiogenic factors are diminished by theaction of Cx, the results are concordant with previous
reports correlating angiogenesis and COX-2 activity [21].
Our immunohistochemical study showed that Cx
caused a decrease in the presence of KI-67 (Figure 4C),
VEGF (Figure 4F) and increased presence of apoptotic
nuclei (Figure 4I) in TA3-MTXR tumor cells. These
effects on the tumor can be explained based on previous
studies. Thus, Ghosh et al. [22] reported that COX-2
activity might activate carcinogens. Moreover, PGE2, the
major downstream effector of COX-2 is associated to
apoptosis inhibition, cell adhesion, tumor growth and
promotes angiogenesis. On the other hand, Tarnawski
and Jones [23] and Rüegg [24] proposed that COX-2 is
an enzyme that synthetize PGs, and their overexpression
and/or PGs production participate actively in the deve-
lopment of angiogenesis and apoptosis inhibition. With
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angiogenesis, reduces tumor growth and promotes apop-
tosis. In our study, Cx inhibits tumor growth, micro-
vascular density and promote apoptosis of tumor cells
resistant to chemotherapy.
Kerbel [25] described the signaling pathway of VEGF,
a potent proangiogenic factor that produces tumor cells
and promotes survival, proliferation and migration of
endothelial cells, critical steps involved in angiogenesis.
Our results showed that Cx reduces VEGF production of
a murine mammary tumor. Moreover, in some organs
where metastasis occurred, such as the lung, VEGF pro-
duction was abundant; especially in certain outlying
areas where tumor cells form nodules but Cx treatment
reduced VEGF levels in that area (data not shown). The
idea that VEGF is reduced with the use of Cx is sup-
ported by Kim et al. [26]; Rodríguez et al. [27] and Vaish
and Sanyal [28] who defined a relation of β-catenin with
COX-2 and survivin.
Brandao et al. [29] reported that short-term COX-2
inhibition by Cx inhibits proliferation reflected by a
reduction of Ki-67 positive cells in patients with breast
cancer. In our study, Cx at 1000 ppm decreases prolife-
ration of a murine mammary tumor resistant to chemo-
therapy using the same marker. The association between
COX-2 activity and proliferation has been previously
proposed. Wu et al. [30] demonstrated that Cx inhibits
proliferation and induces apoptosis via PGE2 pathway.
Jendrossek [31] proposed that the pro-apoptotic effect
of Cx is not only mediated by COX-2 inhibition. Cx
affects apoptotic signaling at multiple levels such as
decreasing expression levels of Mcl-1 and survivin.
Moreover, apoptosis induction by Cx may not depend
on the presence of COX-2. Our results demonstrate that
Cx promotes apoptosis of murine mammary tumor.
Konturek et al. [12] describes that the binding of PGs
to its receptor promotes evasion of apoptosis through
increased survivin and Bcl-2. Moreover, the same binding
might induce VEGF expression through hypoxia inducible
factor 1 alpha (HIF-1α), and cell proliferation and migra-
tion via MAPK. These mechanisms explain at least in part,
the association between VEGF and COX-2/PGs.
The association between PGs and tumorigenesis is
confirmed by Wang and Dubois [32] who showed that
PGs are involved in processes of proliferation and
survival, angiogenesis and migration. Moreover, Dai
et al. [20] and Brandao et al. [29] showed that Celecoxib
inhibits the proliferation of breast cancer.
Cx-treated group results might be explained at least in
part by the effect of Cx on PGs synthesis. 6 days after
inoculation, an obvious but significantly smaller tumor
was developed. These tumor cells produced low levels of
VEGF, because COX-2 action and PG production was
much lower. Although proliferation and VEGF productionwas significantly decreased, it was not completely reduced,
because tumor cells can produce VEGF through other
mechanisms, both genetic and epigenetic. Our results
reinforce the idea that Cx reduces angiogenesis, prolife-
ration and promotes apoptosis, probably through a dimi-
nished PGs production.
Previous reports of antitumor activity of Cx were
assessed in many tumor cell lines. However it has been
poorly investigated the role of Cx in a drug resistant
tumor cell line. The TA3-MTXR cells come from a
mammary murine carcinoma tumor line of ascitic
growth, resistant to many chemotherapeutical drugs, but
mainly to methotrexate (MTX), an antifolate which
prevents the optimal availability of folic acid by the cells,
preventing DNA synthesis and concomitant inability to
replicate [33]. This resistance to MTX does not affect
the action mechanism of Cx, which occurs through
completely different pathways. This can be extrapolated
to the clinical management of patients with tumors
resistant to MTX treatment, where they can receive Cx
treatment and reduce tumor progression [34,35]. On the
other hand, Khan et al. [36] showed that Cx and
continuous low-dose of cyclophosphamide and MTX
provides a little anticancer effect.
These results reinforce the idea of Cx use in the can-
cer treatment either free or through Cx-loaded nano-
particles [37]. On the other hand, it is necessary to
explore a combined treatment between Cx and other
drugs [38,39]. For instance, a new approach could
involve T. cruzi Calreticulin (TcCRT), or derived domains
that inhibit angiogenesis, in several experimental set ups,
and in very low concentrations [40,41].Conclusions
Cx reduces tumor growth in a concentration of 1000
ppm, decreases microvascular density in tumor and
metastatic organs, reduces the presence of VEGF and
promotes apoptosis of multiresistant TA3 tumor cells.
The antiangiogenic and antitumor Cx effects correlate
with its activity on other tumor cell lines, suggesting that
Prostaglandins (PGs) and VEGF production are involved.
Cx could be used alone or combined with other anti-
tumor molecules, ideally aiming to get synergic effects.
For now, Cx is used for some cancer types. However,
future investigations may clarify whether this drug alone
or combined is effective in clinical situations where there
is resistance to MTX.Methods
Animal welfare
Eight week old adult (20–25 g) female A/J strain mice
(n = 12) (Mus musculus) were obtained from our Central
Animal Facility Central Vivarium. Experimental protocols
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Medicine, University of Chile.
Tumor growth assay
The effect of 1000 ppm of Cx on in vivo growth of the
TA3-MTXR murine mammary tumor cell line was
assessed as described previously [42]. Briefly, TA3-
MTXR cells come from a mammary murine carcinoma
tumor cell line of ascitic growth. Methotrexate (MTX)
resistance was performed by weekly passages of ascitic
fluid from mice combined with increasing concentra-
tions of MTX (0.1 to 2.5 mg/kg/48 hrs) until the appro-
priate resistance. Twelve mice were inoculated in the
right lower limb area, at day 0 with 900,000 tumor cells.
At day 6, mice were orally treated with 1000 ppm of Cx
(n = 6) or water as control (n = 6). Width and length of
the tumor was measured with a digital caliper. The
volume was then calculated as previously described [43].
Tumor growth was assessed until 19th day where mice
were euthanized for obtaining tumor and organs samples
for histological procedures. For bioethical rules the
experiment need to be stopped at 19th day.
The experiments were validated by using the Wilcoxon
Signed Rank test (Graph Pad Prism 5). P values < 0.05
were considered as statistically significant.
Drug preparation
Cx (Pfizer Laboratories) was diluted in water at 500,
1000 and 2000 ppm. 1000 ppm concentration was used
in drinking water, as described previously [4].
Immunohistochemistry
Tumor and lung metastasis from the primary tumor
were obtained at 19th day and then fixed in a 10% buff-
ered formalin solution for 48 hours. Serial sections of
5 μm were obtained. In order to evaluate cell prolifera-
tion, a Rabbit Polyclonal Anti – Human Ki-67 antibody
(1:500) (Novocastra, Newcastle Upon Tyne, UK) was
used. Briefly, Ki-67 is a nuclear antigen associated to cel-
lular proliferation. The polyclonal antibody (Novocastra,
Cat#NCL-Ki67-P) binds to Ki-67 antigen in the granular
components of the nucleolus during late G1, S, G2 and
M phases [44]. To detect Vascular Endothelial Growth
Factor (VEGF), an Anti-VEGF165 Polyclonal Antibody
(1:100) (Millipore, CA, USA) was used and then revealed
by the “HistoMouse-MAX Kit” (Invitrogen, Camarillo,
USA) which is based on the use of a secondary antibody
conjugated with horseradish peroxidase and subse-
quently revealed with 3,3′-diaminobenzidine. Relative
Expression was assessed with 30 microscopic fields and
analyzed by Image J Software (NIH, USA). The average
standard error was then calculated and applied to the
t-student test.Evaluation of apoptosis
To evaluate DNA fragmentation (an indicator of apop-
tosis), the FragEL™ DNA Fragmentation Detection Kit
(Calbiochem, Darmstadt, Germany) was used. This
system is based on labeling fragments of DNA of apop-
totic cells by using a TUNEL assay. Histological sections
of tumor and lung metastasis obtained at 19th day were
assessed and apoptotic nuclei were counted in light
microscope.
Microvascular density quantification
To count of blood vessels were counted at 400× in
histological sections from tumors and lungs obtained at
19th day and were stained with Arteta, as described
previously [44].
Chick chorioallantoic membrane (CAM) assay
The CAM assay was performed as described [40].
Briefly, 40 fertilized White Leghorn hen eggs (National
Public Health Institute, Santiago, Chile) were used. The
eggs were incubated for 48 h in a humid 38.5°C atmos-
phere. After extracting 2–3 ml of albumin, a small win-
dow was opened in the egg, in order to allow separation
of the CAM from the shell during the embryo develop-
ment. The window was temporarily sealed with adherent
tape and the eggs were incubated for additional 5 days.
Then, sterile methyl cellulose discs (5 mm diameter,
0.25 μm pore size, 125 μm thickness) (Advantec MFS
Inc., CA, USA), were deposited on the CAMs. Immedi-
ately, 10 μl of Cx at 500, 1000 or 2000 ppm were directly
added onto the filters. The windows were then sealed
and the eggs were incubated for additional 72 h, as indi-
cated above. Then, the CAMs were sliced, following the
filters contours, and fixed in 10% (v/v) formaldehyde.
Tissue sections were prepared by standard procedures
for conventional light microscopy, which aimed to detect
mainly acid polysaccharides, nuclei and cytoskeleton.
Blood vessels were counted in a light microscope with a
1 cm2 micrometric grid, divided in 1 mm2 sections. Ten
of these sections, corresponding to a tissue area of
9000 μm2 were counted. Blood vessels were identified by
their endothelial cells and red blood cells in their lu-
mens. Counting, carried out in a double-blind fashion,
was performed in 35 microscopic fields of CAM tissue
segments, adjacent to the filter edge. One way-ANOVA
with Dunnett’s Multiple Comparison Test was used to
assess the statistical significance, with a confidence inter-
val of 99%.
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